Premium
Folic Acid‐Conjugated 4‐Amino‐Phenylboronate, a Boron‐Containing Compound Designed for Boron Neutron Capture Therapy, is an Unexpected Agonist for Human Neutrophils and Platelets
Author(s) -
Achilli Cesare,
Jadhav Sushilkumar A.,
Guidetti Gianni F.,
Ciana Annarita,
Abbonante Vittorio,
Malara Alessandro,
Fagi Maurizio,
Torti Mauro,
Balduini Alessandra,
Balduini Cesare,
Minetti Giampaolo
Publication year - 2014
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12264
Subject(s) - chemistry , conjugated system , platelet , biocompatibility , boron , pharmacology , folic acid , biochemistry , immunology , organic chemistry , medicine , polymer
Boron neutron capture therapy ( BNCT ) is an anticancer treatment based on the accumulation in the tumor cells of 10 B ‐containing molecules and subsequent irradiation with low‐energy neutrons, which bring about the decay of 10 B to very toxic 7 L i 3+ and 4 H e 2+ ions. The effectiveness of BNCT is limited by the low delivery and accumulation of the used 10 B ‐containing compounds. Here, we report the development of folic acid‐conjugated 4‐amino‐phenylboronate as a novel possible compound for the selective delivery of 10 B in BNCT . An extensive analysis about its biocompatibility to mature blood cells and platelet progenitors revealed that the compound markedly supports platelet aggregation, neutrophil oxidative burst, and inhibition of megakaryocyte development, while it does not have any manifest effect on red blood cells.